---
figid: PMC7598629__cancers-12-02751-g001
figtitle: PI3K/AKT/mTOR signalling pathway SMIs for the treatment of endometrial cancer
organisms:
- NA
pmcid: PMC7598629
filename: cancers-12-02751-g001.jpg
figlink: pmc/articles/PMC7598629/figure/cancers-12-02751-f001/
number: F1
caption: 'PI3K/AKT/mTOR signalling pathway SMIs for the treatment of endometrial cancer.
  Current SMIs under clinical investigation and their target molecules are displayed.
  Abbreviations: RTK, Receptor Tyrosine Kinase.'
papertitle: Small-Molecule Inhibitors (SMIs) as an Effective Therapeutic Strategy
  for Endometrial Cancer.
reftext: Cristina Megino-Luque, et al. Cancers (Basel). 2020 Oct;12(10):2751.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9050466
figid_alias: PMC7598629__F1
figtype: Figure
organisms_ner:
- NA
redirect_from: /figures/PMC7598629__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7598629__cancers-12-02751-g001.html
  '@type': Dataset
  description: 'PI3K/AKT/mTOR signalling pathway SMIs for the treatment of endometrial
    cancer. Current SMIs under clinical investigation and their target molecules are
    displayed. Abbreviations: RTK, Receptor Tyrosine Kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SAR245408
  - NVP BLY719
  - AZD5363
  - AZD2014
  - AZD8055
  - Sapanisertib
  - Everolimus
  - RADO01
  - Temserolimus
  - Ridaforolimus
  - Deforolimus
  - AP23573
  - BEZ235
  - GDC-0980
  - PF05212384
---
